Preventing kidney injury from strong medications with cilastatin
Part of Kidney & urinary, Women’s health & pregnancy clinical trials.
This study tests whether a medicine called cilastatin can prevent kidney damage caused by certain strong medications. If you are receiving one of these medications and are at risk for kidney injury, this trial may offer protection.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older
- You are currently receiving a medication that can harm the kidneys, such as certain intravenous antibiotics, anti-rejection drugs, or chemotherapy, or you are getting contrast dye through an artery with at least two other high-risk drugs
- You do not have severe kidney injury or advanced chronic kidney disease (stage 5)
- You are not pregnant or breastfeeding
- You are not allergic to imipenem-cilastatin
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests ways to protect the kidneys in intensive-care patients who have moderate or severe acute kidney injury. If you are on a ventilator or medications to support blood pressure, this study may offer extra kidney care to help prevent further damage.
This study looks at how cisplatin chemotherapy affects the kidneys. It may help doctors better predict and protect against kidney damage when patients start cisplatin.
This trial tests whether the drug infliximab can help treat kidney damage caused by immunotherapy (checkpoint inhibitors). It is for people whose kidneys suddenly fail due to inflammation, and who haven't already had strong immune-suppressing treatment for this problem.
This trial tests whether taking N-acetylcysteine (NAC, a common supplement) can help protect your kidneys during cisplatin-based chemotherapy. It may reduce the risk of kidney damage often caused by this strong cancer drug.
This trial compares two common antibiotic combinations to see which one is less likely to cause kidney injury in hospitalized patients. You may be eligible if you need treatment with vancomycin plus either piperacillin-tazobactam or cefepime.
This study tests how safe a specific blood thinner called “citrate” is when used during continuous kidney dialysis (CRRT) for people with AKI or kidney failure. If you qualify, your care team will compare citrate safety against standard approaches to see if it’s tolerable and safe.
Hear when a new Acute Kidney Injury trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.